Aurobindo Pharma Limited

P. V. Ram Prasad Reddy

Chairman, Aurobindo Pharma USA

K. Nithyananda Reddy

Vice Chairman and Managing Director of Aurobindo

Santhanam Subramanian

Chief Financial Officer, Aurobindo Pharma

Sanjeev Dani

COO & Head Formulations, Aurobindo Pharma Limited

Yugandhar Puvvala

CEO of Eugia Pharma Specialties Limited

Swami Iyer

CFO, Aurobindo Pharma USA

Deepti Thakur

Investor Relations & Corporate Communications,

INR 6,235.9

f the fiscal year FY23 declared by the company. For Q1 FY23, the company registered a revenue of INR 6,235.9 Cr, an increase of 9.4% year- on-year, the EBITDA before forex and other income was INR 964.7 Cr dec

9.4%

by the company. For Q1 FY23, the company registered a revenue of INR 6,235.9 Cr, an increase of 9.4% year- on-year, the EBITDA before forex and other income was INR 964.7 Cr declined by 1% quarter- on

INR 964.7

of INR 6,235.9 Cr, an increase of 9.4% year- on-year, the EBITDA before forex and other income was INR 964.7 Cr declined by 1% quarter- on-quarter, EBITDA margin for the quarter was 15.5%. Net profit decreased

1%

crease of 9.4% year- on-year, the EBITDA before forex and other income was INR 964.7 Cr declined by 1% quarter- on-quarter, EBITDA margin for the quarter was 15.5%. Net profit decreased by 9.6% quarter-

15.5%

other income was INR 964.7 Cr declined by 1% quarter- on-quarter, EBITDA margin for the quarter was 15.5%. Net profit decreased by 9.6% quarter- on-quarter to INR 520.5 Cr. In terms of the business break

9.6%

eclined by 1% quarter- on-quarter, EBITDA margin for the quarter was 15.5%. Net profit decreased by 9.6% quarter- on-quarter to INR 520.5 Cr. In terms of the business breakdown, formulation business in

INR 520.5

arter, EBITDA margin for the quarter was 15.5%. Net profit decreased by 9.6% quarter- on-quarter to INR 520.5 Cr. In terms of the business breakdown, formulation business in Q1 FY23 witnessed a growth of 9%

9%

.5 Cr. In terms of the business breakdown, formulation business in Q1 FY23 witnessed a growth of 9% year-on-year, to INR 5,329.4 Cr and contributed around 85.5% of the total revenue.

INR 5,329.4

the business breakdown, formulation business in Q1 FY23 witnessed a growth of 9% year-on-year, to INR 5,329.4 Cr and contributed around 85.5% of the total revenue. API business c

85.5%

usiness in Q1 FY23 witnessed a growth of 9% year-on-year, to INR 5,329.4 Cr and contributed around 85.5% of the total revenue. API business contributed around 14.5% of the

14.5%

around 85.5% of the total revenue. API business contributed around 14.5% of the total revenue and clocked a revenue of INR 906.5 Cr for the quarter registering a growth of

INR 906.5

API business contributed around 14.5% of the total revenue and clocked a revenue of INR 906.5 Cr for the quarter registering a growth of 11.6% on a year-on-year basis led by improved demand for